Literature DB >> 15981025

Incadronate disodium inhibits joint destruction and periarticular bone loss only in the early phase of rat adjuvant-induced arthritis.

Tomoyuki Akiyama1, Satoshi Mori, Tasuku Mashiba, Kensaku Miyamoto, Satoshi Komatsubara, Yongping Cao, Takeshi Manabe, Hiromichi Norimatsu, Hiroaki Dobashi, Michiaki Tokuda.   

Abstract

Destruction of articular cartilage and subchondral bone loss in the affected joints of rat adjuvant arthritis have never been quantified histologically. This study aimed to evaluate the effect of incadronate disodium on joint destruction and periarticular bone loss, using histomorphometric measurements. Seven-week-old female Lewis rats were injected with 0.1 mg of heat-killed Mycobacterium butyricum into the tail base. Immediately after sensitization, vehicle, or incadronate at 10 or 100 microg/kg per day, was administered subcutaneously, three times per week. Hind-paw volume was measured weekly and the animals were killed at 2, 4, 6, and 10 weeks after sensitization. After taking X-rays, decalcified sagittal sections of the ankle joint were prepared and stained with toluidine blue and tartarate-resistant acid phosphatase. Articular cartilage destruction and subchondral bone loss were evaluated histomorphometrically. At 2 weeks after sensitization, no radiographic or histologic changes were observed. However, at 4 weeks, severe articular cartilage destruction and subchondral bone loss were found in the arthritic control group, while these changes were inhibited dose-dependently by incadronate treatment. At 6 and 10 weeks, both the destructive changes and the bone loss had further progressed, and they were not inhibited by incadronate treatment. Incadronate dose-dependently inhibited articular cartilage destruction and subchondral bone loss at 4 weeks after sensitization in this adjuvant arthritis model. However, the suppressive effects of incadronate did not continue until 6 and 10 weeks.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15981025     DOI: 10.1007/s00774-004-0602-3

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  35 in total

1.  Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation.

Authors:  S Kotake; K Sato; K J Kim; N Takahashi; N Udagawa; I Nakamura; A Yamaguchi; T Kishimoto; T Suda; S Kashiwazaki
Journal:  J Bone Miner Res       Date:  1996-01       Impact factor: 6.741

Review 2.  Bone and joint destruction in rheumatoid arthritis: what is really happening?

Authors:  Steven R Goldring
Journal:  J Rheumatol Suppl       Date:  2002-09

3.  Effect of clodronate on established adjuvant arthritis.

Authors:  T Osterman; K Kippo; L Laurén; R Hannuniemi; R Sellman
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

4.  A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone.

Authors:  D Thiébaud; P Jaeger; C Gobelet; A F Jacquet; P Burckhardt
Journal:  Am J Med       Date:  1988-08       Impact factor: 4.965

5.  Mineral metabolism and bone mineral content in rheumatoid arthritis. Effect of corticosteroids.

Authors:  A D'Angelo; A Fabris; L Sartori; L Malvasi; P Travaglia; P F Gambari; S Todesco
Journal:  Clin Exp Rheumatol       Date:  1985 Apr-Jun       Impact factor: 4.473

6.  Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis.

Authors:  Petra Herrak; Birgit Görtz; Silvia Hayer; Kurt Redlich; Erika Reiter; Jürg Gasser; Helga Bergmeister; Giorgos Kollias; Josef S Smolen; Georg Schett
Journal:  Arthritis Rheum       Date:  2004-07

7.  Long-term amelioration of rat adjuvant arthritis following systemic elimination of macrophages by clodronate-containing liposomes.

Authors:  R W Kinne; C B Schmidt-Weber; R Hoppe; E Buchner; E Palombo-Kinne; E Nürnberg; F Emmrich
Journal:  Arthritis Rheum       Date:  1995-12

8.  Double blind radiological assessment of continuous oral pamidronic acid in patients with rheumatoid arthritis.

Authors:  A Maccagno; E Di Giorgio; E J Roldan; L E Caballero; A Perez Lloret
Journal:  Scand J Rheumatol       Date:  1994       Impact factor: 3.641

9.  Bisphosphonate whole body retention test: relations to bone mineralization rate, renal function and bone mineral content in osteoporosis and metabolic bone disorders.

Authors:  L Mosekilde; C Hasling; P C Tågehøj Jensen; F Tågehøj Jensen
Journal:  Eur J Clin Invest       Date:  1987-12       Impact factor: 4.686

10.  Treatment of rat arthritides with clodronate-containing liposomes.

Authors:  R W Kinne; C B Schmidt; E Buchner; R Hoppe; E Nürnberg; F Emmrich
Journal:  Scand J Rheumatol Suppl       Date:  1995
View more
  1 in total

1.  Arthralgia in 329 Patients Taking Aromatase Inhibitors.

Authors:  Yoshiya Horimoto; Mitsue Saito; Fujio Kasumi
Journal:  Breast Care (Basel)       Date:  2009-09-21       Impact factor: 2.860

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.